

Stanislav Sitkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7339182/publications.pdf>

Version: 2024-02-01

53
papers

382
citations

933447

10
h-index

888059

17
g-index

71
all docs

71
docs citations

71
times ranked

439
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, 1, 4-52.	0.4	63
2	Clinical Potential of Anti-inflammatory Effects of <i>Faecalibacterium prausnitzii</i> and Butyrate in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, e40-e41.	1.9	33
3	Microbiome, gut dysbiosis and inflammatory bowel disease: That moment when the function is more important than taxonomy. Al'manah Klinicheskoy Meditsiny, 2018, 46, 396-425.	0.3	26
4	Whole-Genome Sequencing of <i>Lactobacillus helveticus</i> D75 and D76 Confirms Safety and Probiotic Potential. Microorganisms, 2020, 8, 329.	3.6	20
5	Management of patients with digestive diseases during the COVID-19 pandemic: Clinical Practice Guidelines by the Gastroenterological Scientific Society of Russia. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2020, , 4-51.	0.4	20
6	Acceptive Immunity: The Role of Fucosylated Glycans in Human Host-Microbiome Interactions. International Journal of Molecular Sciences, 2021, 22, 3854.	4.1	15
7	Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, , 5-117.	0.4	15
8	How to Increase the Butyrate-producing Capacity of the Gut Microbiome: Do IBD Patients Really Need Butyrate Replacement and Butyrogenic Therapy?. Journal of Crohn's and Colitis, 2018, 12, 881-882.	1.3	12
9	METABOLIC DYSBIOSIS OF THE GUT MICROBIOTA AND ITS BIOMARKERS. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2016, 12, 6-29.	0.4	12
10	Metabolomics: the perspective search of methods to overcome infertility. Gynecological Endocrinology, 2015, 31, 79-82.	1.7	11
11	Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes. Neurogastroenterology and Motility, 2021, 33, e14038.	3.0	10
12	Gastrointestinal microbiome and <i>Helicobacter pylori</i> : Eradicate, leave it as it is, or take a personalized benefit-risk approach?. World Journal of Gastroenterology, 2022, 28, 766-774.	3.3	10
13	P852 A metabolomics approach to discover biomarkers of chronic intestinal inflammation associated with gut microbiota dysbiosis in ulcerative colitis and Celiac Disease. Journal of Crohn's and Colitis, 2018, 12, S547-S548.	1.3	9
14	Complete Genome Sequences of the Probiotic Lactic Acid Bacteria <i>Lactobacillus helveticus</i> D75 and D76. Genome Announcements, 2018, 6, .	0.8	9
15	Alterations in Polyunsaturated Fatty Acid Metabolism and Reduced Serum Eicosadienoic Acid Level in Ulcerative Colitis: Is There a Place for Metabolomic Fatty Acid Biomarkers in IBD?. Digestive Diseases and Sciences, 2018, 63, 2480-2481.	2.3	9
16	Gut Microbiota as a Host Defender and a Foe: The 2 Faces of Commensal <i>Bacteroides thetaiotaomicron</i> in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, e71-e71.	1.9	8
17	Gut Microbiota-Mediated Pleiotropic Effects of Fucose Can Improve Inflammatory Bowel Disease by Modulating Bile Acid Metabolism and Enhancing Propionate Production. Inflammatory Bowel Diseases, 2021, 27, e10-e11.	1.9	7
18	Management of patients with digestive diseases during the COVID-19 pandemic. Clinical Practice Guidelines by the Russian scientific medical society of internal medicine (RSMSIM) and the Gastroenterological Scientific Society of Russia (2nd edition). Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, , 5-82.	0.4	6

#	ARTICLE	IF	CITATIONS
19	Metabolomic Biomarkers in Gynecology: A Treasure Path or a False Path?. <i>Current Medicinal Chemistry</i> , 2020, 27, 3611-3622.	2.4	6
20	Russian Consensus "Hyperammonemia in Adults" (Version 2021). <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2021, , 97-118.	0.4	5
21	Clinical guidelines "Chronic diarrhea in adults". <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2021, , 7-67.	0.4	5
22	Modern understanding of adult celiac disease. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2021, , 84-95.	0.4	5
23	Low-molecular-weight components of the metabolome control the proliferative activity in cellular and bacterial cultures. <i>Doklady Biological Sciences</i> , 2017, 472, 8-10.	0.6	4
24	A proposed treatment algorithm for mild to moderate ulcerative colitis" with an emphasis on budesonide foam and mucosal healing. <i>Journal of Gastroenterology</i> , 2018, 53, 799-800.	5.1	4
25	P399 Oral butyrate plus inulin improve serum metabolomic profile and gut microbiota composition in ulcerative colitis and celiac disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S232.	1.3	3
26	Bad "Good" Bile Acids and Gut Microbiota Dysbiosis in Inflammatory Bowel Disease: Mice and Humans Are Not the Same. <i>Digestive Diseases and Sciences</i> , 2021, 66, 925-927.	2.3	3
27	Treatment Options for Patients with Gallstones (Cholelithiasis). <i>Meditinskiy Sovet</i> , 2019, , 44-51.	0.5	3
28	154 MINIMAL HEPATIC ENCEPHALOPATHY: POSSIBILITIES OF DIETARY FIBERS TREATMENT. <i>Journal of Hepatology</i> , 2012, 56, S67.	3.7	2
29	Altered Sphingolipid Metabolism and its Interaction With the Intestinal Microbiome Is Another Key to the Pathogenesis of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e157-e158.	1.9	2
30	Biliary sludge: pathogenesis, etiology and drug therapy. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 179-186.	0.8	2
31	Necrotizing enterocolitis: current concepts of etiopathogenesis with an emphasis on microbiome and metabolomics. <i>Voprosy Prakticheskoi Pediatrii</i> , 2021, 16, 98-105.	0.2	2
32	P749. Not only butyrate-producing bacteria but possibly also <i>Bacteroides thetaiotaomicron</i> protects against ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, S489.2-S489.	1.3	1
33	Intestinal microbiota and dysbiosis in celiac disease. <i>Rossiyskiy Vestnik Perinatologii I Pediatrii</i> , 2021, 66, 116-122.	0.3	1
34	Functional polymorphism of the serotonin reuptake transporter SLC6A4 gene in various clinical variants of irritable bowel syndrome. <i>Al'manah Klinicheskoy Meditsiny</i> , 2019, 47, 496-504.	0.3	1
35	Crohn's disease with isolated gastric involvement as an example of a rare disease phenotype: a clinical case. <i>Al'manah Klinicheskoy Meditsiny</i> , 2019, 47, 592-602.	0.3	1
36	The role of bacterial metabolites derived from aromatic amino acids in non-alcoholic fatty liver disease. <i>Al'manah Klinicheskoy Meditsiny</i> , 2020, 48, 375-386.	0.3	1

#	ARTICLE	IF	CITATIONS
37	IDENTIFICATION OF BACTERIOCIN GENES IN PROBIOTIC STRAINS OF LACTIC ACID BACTERIA LACTOBACILLUS ACIDOPHILUS D-75 AND LACTOBACILLUS ACIDOPHILUS D-76. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2016, , 58-65.	0.4	1
38	Cytokine profile and immunological status of patients with ulcerative colitis. Voprosy Prakticheskoi Pediatrii, 2021, 16, 52-62.	0.2	1
39	CE with Cu ²⁺ ions and 2-hydroxypropyl-β-cyclodextrin additives for the investigation of amino acids composition of the culture medium in a cellular model of non-alcoholic fatty liver disease. Journal of Pharmaceutical and Biomedical Analysis, 2022, 213, 114663.	2.8	1
40	FRI-266-Saccharomyces boulardii modulates the colonic microbiota towards a more favourable composition in patients with non-alcoholic fatty liver disease (simple steatosis). Journal of Hepatology, 2019, 70, e511.	3.7	0
41	P841 Small intestinal bacterial overgrowth in patients with Crohn's disease is not only associated with a more severe disease, but is also marked by dramatic changes in the gut microbiome. Journal of Crohn's and Colitis, 2019, 13, S544-S544.	1.3	0
42	Acne as a common extraintestinal manifestation of celiac disease. Treatment approaches. Meditsinskiy Sovet, 2021, , 126-135.	0.5	0
43	Blood serum metabolomic assessment – a perspective diagnostic method for non-alcoholic fatty liver disease in men. HERALD of North-Western State Medical University Named After I I Mechnikov, 2018, 10, 5-14.	0.2	0
44	Risk factors for developing diastolic dysfunction in nonalcoholic steatohepatitis. Archiv Euromedica, 2019, 9, 104-105.	0.2	0
45	Report on the work of the 1st stage of the XXIII Congress of the Scientific Society of Gastroenterologists of Russia (GSSR) (St. Petersburg, June 10-11, 2020). Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2020, , 167-168.	0.4	0
46	Identification of Antihypertensive Tripeptides in the Culture Medium of Lactobacillus helveticus D75 and D76 Strains. , 2020, 61, .		0
47	Magnetic resonance imaging and other medical imaging techniques in the diagnosis of gallstones. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2022, , 28-34.	0.4	0
48	Chronic pancreatitis and the intestinal microbiome in adults and children: Not only SIBO but also gut dysbiosis has clinical significance. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2022, , 125-133.	0.4	0
49	NUTRITIONAL FACTORS OF ANEMIA IN ULCERATIVE COLITIS PATIENTS. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2016, , 19-25.	0.4	0
50	FUNCTIONAL FOODS ARE CRITICAL COMPONENTS OF TREATMENT OF METABOLIC DISORDERS IN CELIAC DISEASE. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2016, 12, 42-49.	0.4	0
51	Gluten-related disorders: current concepts. Part 1. Voprosy Prakticheskoi Pediatrii, 2021, 16, 103-110.	0.2	0
52	<i>Helicobacter pylori&/i>. The survival strategy of a commensal symbiont in the <i>Homo sapiens&/i> population. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, , 102-108.	0.4	0
53	Gluten-related disorders: current concept. Part 2. Voprosy Prakticheskoi Pediatrii, 2022, 17, 190-195.	0.2	0